» Articles » PMID: 19487253

Changes in MRNA Expression Levels of Solute Carrier Transporters in Inflammatory Bowel Disease Patients

Overview
Specialty Pharmacology
Date 2009 Jun 3
PMID 19487253
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease (IBD) is an inflammatory condition that affects the gastrointestinal tract. The solute carrier (SLC) superfamily of transporters comprise proteins involved in the uptake of drugs, hormones, and other biologically active compounds. The purpose of this study was to determine the mRNA expression levels of 15 solute carrier transporters in two regions of the intestine in IBD patients. Endoscopic biopsy specimens were taken from two locations (terminal ileum and colon) for histological examination and RNA extraction. We quantitatively measured the mRNA expression of 15 SLC transporters in 107 IBD patients (53 with Crohn's disease and 54 with ulcerative colitis) and 23 control subjects. mRNA expression was evaluated using the quantitative reverse transcription-polymerase chain reaction technique. We observed that in the ileum of IBD patients, mRNA levels for serotonin transporter, equilibrative nucleoside transporter (ENT) 1, ENT2, and organic anion-transporting polypeptide (OATP) 2B1 were significantly elevated, whereas levels for apical sodium-dependent bile acid transporter (ASBT) and organic zwitterion/cation transporter (OCTN) 2 were significantly lower. In colon, mRNA levels for ENT1, ENT2, concentrative nucleoside transporter (CNT) 2, OATP2B1, and OATP4A1 were significantly higher, whereas mRNA levels for OCTN2 were significantly decreased. In inflamed colon of IBD patients the mRNA expression levels of ENT1, ENT2, CNT2, OATP2B1, OATP4A1, and peptide transporter 1 were significantly higher. We conclude that intestinal SLC mRNA levels are dysregulated in IBD patients, which may be linked to the inflammation of the tissue and provides an indication about the role of inflammatory signaling in regulation of SLC expression.

Citing Articles

Cytosolic delivery of innate immune agonists.

Bharadwaj R, Jaiswal S, Silverman N Trends Immunol. 2024; 45(12):1001-1014.

PMID: 39567309 PMC: 11624987. DOI: 10.1016/j.it.2024.10.007.


Novel Expression of Apical Bile Acid Transport (ASBT) More Proximally Than Distal Ileum Contributing to Enhanced Intestinal Bile Acid Absorption in Obesity.

Sundaram S, Jagadeesan A, Paulraj R, Sundaram U, Arthur S Int J Mol Sci. 2024; 25(21).

PMID: 39519005 PMC: 11547122. DOI: 10.3390/ijms252111452.


Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.

Walraven T, Busch M, Wang J, Donkers J, Duijvestein M, van de Steeg E Arch Toxicol. 2024; 98(11):3519-3541.

PMID: 39249550 PMC: 11489187. DOI: 10.1007/s00204-024-03844-w.


Inflammation and Organic Cation Transporters Novel (OCTNs).

Pochini L, Galluccio M, Console L, Scalise M, Eberini I, Indiveri C Biomolecules. 2024; 14(4).

PMID: 38672410 PMC: 11048549. DOI: 10.3390/biom14040392.


The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling.

Alsmadi M, Abudaqqa A, Idkaidek N, Qinna N, Al-Ghazawi A AAPS PharmSciTech. 2024; 25(4):86.

PMID: 38605192 DOI: 10.1208/s12249-024-02803-z.